Johnson & Johnson Vision Announces Launch of Elita Platform to Correct Myopia with New SILK Procedure

Johnson & Johnson Vision will launch the new Elita Platform at European Society of Cataract and Refractive Surgeons (ESCRS) Congress, September 8-12, 2023, in Vienna, Austria.

The Elita Platform enables surgeons to perform refractive correction on patients with myopia, with or without astigmatism, using the new SILK (Smooth Incision Lenticule Keratomileusis) procedure. J&J Vision says with an ultra-precise laser pulse and fast laser delivery system, the Elita provides surgeons with a consistently smooth and easy lenticular removal, offering exceptional vision correction with next-day results and recovery.[1,2,3]

The SILK procedure is designed to helps correct myopia through a quick and minimally invasive process. The Elita femtosecond laser uses fine laser pulses to gently create a lenticule in the cornea after the eye is numbed. The lenticule is then delicately removed through a microscopic incision and the smooth lenticule removal reshapes the cornea, correcting the eye.[1,2]

According to J&J Vision, an integrated blend of technologies enables surgeons to perform the SILK procedure precisely to yield next-day results for patients.[1,2]

• Ultra-Precise Pulse delivers better quality treatment of corneal tissue[1]
• Ultra-Fast Delivery System enables contiguous placement of laser pulses for exceptionally smooth tissue surface
• Sub-Micron Digital-Encoder Controlled Scanning System allows a high-degree of pulse placement and superior optical performance across the entire treatment area[1]
• Industry-first biconvex lenticule: Designed for better quality of vision. Reduces cutting of corneal nerves and provides fast regeneration for a healthy ocular surface

Elita Femtosecond Laser has FDA 510(k) approval in the US for FLAP procedures only.

The Johnson & Johnson Vision ESCRS Booth (#B202) will have live demonstration areas for surgeons to experience first-hand the Elita Femtosecond Laser as well as other leading Johnson & Johnson Vision products. Additionally, attendees will be able to participate in the Toric VR Simulator experience alongside dry labs and meet the expert sessions at the booth and in the Johnson & Johnson Vision Lighthouse.

Key scientific abstracts supported by Johnson & Johnson Vision

The congress will also see over 30 scientific communications from both Johnson & Johnson Vision sponsored studies and investigator-initiated studies (IIS) being presented, including:

Elita Femtosecond Laser

• Epithelial Corneal Nerves and Stromal Wound Healing Post Lenticular Extraction Using New Femtosecond Laser
• Evaluation Ease of Lenticule Removal and Visual Outcomes After a Lenticule Procedure with Elita Femtosecond Laser Platform

Tecnis Eyhance Intraocular Lens

• Performance Comparative of Monofocal IOL with Enhanced Features for Intermediate Vision to Current Standard Monofocal Lens
• A Scoping Review On The Placement Of Enhanced Monofocal Between Conventional And Extended Depth Of Focus Intraocular Lenses

Tecnis Synergy Intraocular Lens

• Safety And Efficacy Outcomes With A New Continuous-Range-Of-Vision Intraocular Lens

Tecnis Synergy Toric II Intraocular Lens

• 6 Month Follow Up Comparison Of Rotational Stability Between Zeiss At Lisa 939 And Synergy Toric II For Correction Of Anisometropia With Astigmatism And Presbyopia
• Refractive Results After Cataract Surgery And Implantation Of A Trifocal Intraocular Lens– Model DFW-375 Tecnis Synergy Toric

Tecnis Symfony and Tecnis Symfony OptiBlue Intraocular Lenses

• Impact of Violet Light Filtration and High-Resolution Lathing on the Clinical Performance of a Diffractive Extended Depth of Focus IOL

A complete listing is available at: https://congress.escrs.org/programme/online-programme/

Other representatives from Johnson & Johnson Vision will be participating in events throughout ESCRS 23, including ESCRS iNovation Day on the 8th at the Messe Wien Exhibition & Congress Centre.

Jacqueline Henderson, President EMEA, Johnson & Johnson Vision will be taking part in the 'European industry leadership roundtable on visions for the next 5 years;' Raj Rajpal, Chief Medical Officer, Johnson & Johnson Vision, will be joining the 'Managing presbyopia from early stage to cataracts panel discussion;' Xiao Yu Song, Global Head of R&D, Johnson & Johnson Vision will discuss 'Myopia: The next pandemic;' and Tobin Island, Senior Director, Laser and Software, Johnson & Johnson Vision will be talking about the re-emergence of refractive surgery: lenticule extraction and phakic IOLs.

Education and interactive sessions

Johnson & Johnson Vision is also hosting a series of educational and interactive sessions aimed at sparking coversation and providing an opportunity to share, discuss and learn from leading experts in the field of ophthalmology. These include:

• EuroTimes Satellite Symposium – SILK: Re-Defining Technology Innovation with the New Elite in Laser Refractive Surgery. Room Strauss 3. 9th September, 13.00-14.00
• IME Symposia – Demystifying Common Misunderstandings with Refractive IOL Procedures. Room A3. 9th September, 16.30-17.30
• IME Symposia – The Future of Refractive Surgery, Lenticle Extraction, Phakic IOLs and Beyond. Room A3. 10th September 2023, 09.30-10.30
• EuroTimes Satellite Symposia – Regaining Pure Vision in Intermediate Contrast. Room A4. 10th September, 13.00-14.00

For more information visit the Johnson & Johnson Vision booth #B202.

References

1. DOF2023RF4002. ELITA^TM Femtosecond Laser Device Description
2. DOF2023RF4003. ELITA™ femtosecond laser SILK™ procedure long term safety and effectiveness – Subset of Phase 3 data (India sites only)
3. ARVO 2023 LASIK Flap Accuracy Comparison Between A New Femtosecond Laser and iFS, Mahipal Sachdev
4. Flitcroft DI et al. IMI–Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60:M20-30.
5. Donovan L, Sankaridurg P, Ho A et al. Myopia progression rates in urban children wearing single-vision spectacles. OVS 2012;89(1):27-32.
6. ** Pärssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmologica. 2019;97(5):510-518.
7. ‡‡ Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of Age at Myopia Onset with Risk of High Myopia in Adulthood in a 12-Year Follow-up of a Chinese Cohort. Jama Ophthalmol. 2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451.
8. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo K, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmol.
   2016;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.